Ligon Discovery Sees Bayer-Schering Deal as Springboard to More Pharma Partnerships

Ligon is "pleased" with its partnership, not only because of the revenue stream it will provide the year-old Harvard University spinout, but because it could lead to similar partnerships with other pharmaceutical clients.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.